Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Treatment Without Consent?

January 15, 2015
By Paul R. Helft, MD
Publication
Article
OncologyOncology Vol 29 No 1
Volume 29
Issue 1

A delirious head and neck cancer patient does not have the capacity to make treatment decisions. Can we begin palliative radiation therapy without his consent?

Paul R. Helft, MD

I received in transfer a man in his 50s with advanced base of the tongue cancer. He has a long history of complex mental illness and lives in a very difficult set of social circumstances. His head and neck cancer has clearly been neglected, because at this time it is occupying a large part of the floor of his mouth and pushing his tongue outside of his lips. He has extensive locoregional invasion and a great deal of pain, and was found on admission to have distant metastases in the lungs. He has a feeding tube, which was inserted at another hospital, and he recently underwent tracheostomy because of airway compromise. Probably because of his acute illness, opiate pain medicines, and his pre-existing mental illness, he is delirious, and I do not think that he has the decision-making capacity needed to make treatment decisions. I obtained a psychiatry consultation, and the psychiatrist agreed that he lacks decision-making capacity for complex decisions. He has no identifiable family or other surrogates, and there is no one who has power of attorney for healthcare decisions. I have asked the hospital attorney to begin the process of obtaining a guardian ad litem from the court, but she informed me that this process would take a week or more to complete. In the meantime, can we begin palliative radiation therapy for symptom relief without his consent?

Dr. Helft Responds

The main ethical issue at stake in this tragic story is surrogate decision making, which is an incredibly common clinical issue. A recent study by one of my own colleagues found that, among hospitalized patients over 65, almost half required a major surrogate decision during their index hospitalization. In very rough outline, one can think of three levels of surrogate decision making for incapacitated patients such as your patient. The first is when we use the patient’s own advance wishes, such as wishes spelled out in a living will or advance directive document. This level has the advantage of using information obtained directly from the patient. The second is often referred to as substituted judgment, and is by far the most common situation. Such situations occur when a patient lacks decision-making capacity for a given decision and we turn to legally authorized surrogates to put themselves in the patient’s place and make the decision. This might be a person who has been legally designated to have durable power of attorney for healthcare decisions, or more commonly, it might be a family member with legal standing to make decisions, such as a spouse or first-degree relative. Statutes vary from state to state, however, with regard to who is designated as a legal surrogate, so you will need to consult your hospital attorney to guide you in such situations. The last level of surrogate decision making is usually called the “best interest” approach, and is based on the idea that, when no one else is available, the deciding clinician must keep the best interests of the patient in central focus.

Your patient’s situation requires this last approach, I think, since radiation therapy is likely to provide some palliative benefit, and the longer you wait to begin it, the longer the patient’s suffering will continue. Such a “best interest” approach necessitates careful consideration of the risk-benefit ratio of the treatment in question. In this context, relatively innocuous treatments (eg, opiate pain management) require a different level of consideration than more invasive or dangerous interventions (eg, surgery). Radiation therapy probably falls somewhere in the middle of this spectrum. I think that, in the context you describe, out of consideration for the patient’s best interest, the most beneficent approach would entail radiation therapy as part of a comprehensive approach to this patient’s palliative care. So I believe it is ethical to begin radiation therapy without the patient’s explicit consent. However, I applaud the decision to obtain a court-appointed guardian who will be able to help with future decisions.

Disclaimer:The advice offered in this ethical consultation feature is based solely on the information supplied by readers, and is offered without benefit of a detailed patient history or physical or laboratory findings. The information is offered as a discussion of ethical issues and is not intended to be medical or legal advice and, therefore, should not be considered complete or used in place of a formal ethics consultation or in place of seeking advice from your ethics committee, legal counsel, or other available resources. One should never disregard or change medical advice or delay in providing it because of something that is printed here. The opinions expressed here are only those of the author and do not reflect the viewpoint of ONCOLOGY.

This case was originally published online August 18, 2014.

Articles in this issue

Chemotherapy for Soft-Tissue Sarcomas
Treatment Without Consent?
Treatment Without Consent?
Osteoclast Inhibitors: A Multifaceted Tool in the Management of Breast Cancer
The Role of Bisphosphonates in Early- and Advanced-Stage Breast Cancer: Have We Finally Optimized Care?
The Double-Edged Sword of ADT: Emerging Evidence of Cardiovascular, Pulmonary, and Renal Risks
Cytotoxic Chemotherapy for Adult Soft-Tissue Sarcomas: A Lesson in Humility
Chemotherapy in Soft-Tissue Sarcoma: Where Do We Go From Here?
Bisphosphonates in Breast Cancer: A Triple Winner?
Bisphosphonates: Game Changers?
Big Data: Not Really the Same as Level 1 Data
ADT Risks and Side Effects in Advanced Prostate Cancer: Cardiovascular and Acute Renal Injury
ADT Risks and Side Effects in Advanced Prostate Cancer: Cardiovascular and Acute Renal Injury
Recent Videos
Related Content
Advertisement

3 Things You Should Know About Unresectable NSCLC

3 Things You Should Know About Unresectable NSCLC

ONCOLOGY Staff
April 21st 2025
Article

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Michelle Sosa;Deirdre McNicholas;Arbelina Bebla;Seth Emont;Zhun Cao;Manu Tyagi;Craig Lipkin;Sommer Gunia
April 19th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.


97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

Chia Jie Tan;Connor Willis;Trang Au;Matthew Schabath, PhD;Chenghui Li;Kristen Kelley;Xiaoqing Xu;Leah Park;Clara Lam;Sandhya Mehta;Jackie Kwong;Diana Brixner;David Stenehjem
April 17th 2025
Article
Related Content
Advertisement

3 Things You Should Know About Unresectable NSCLC

3 Things You Should Know About Unresectable NSCLC

ONCOLOGY Staff
April 21st 2025
Article

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Michelle Sosa;Deirdre McNicholas;Arbelina Bebla;Seth Emont;Zhun Cao;Manu Tyagi;Craig Lipkin;Sommer Gunia
April 19th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.


97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

Chia Jie Tan;Connor Willis;Trang Au;Matthew Schabath, PhD;Chenghui Li;Kristen Kelley;Xiaoqing Xu;Leah Park;Clara Lam;Sandhya Mehta;Jackie Kwong;Diana Brixner;David Stenehjem
April 17th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.